Mizagliflozin

Mizagliflozin has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest story, Nov 6, 2026: “Canagliflozin reduced calcium buildup in mouse arteries”.

Intervention

1 paper studies itUpdated

1 new paper in 30 daysSee all 1 papers on mizagliflozin

At a glance

2 trials, 1 about aging.

Cells, worms or flies, mice and humans: nothing yet.
  • 2 trials, 1 about aging
  • 2 of 2 trials sponsored by its developers
  • Animals1

Has mizagliflozin been tested in people?

1 of 2 about aging

No study of it in people has been published yet.

Who is developing mizagliflozin?

1 company: Vogenx.

Companies
  • VogenxPhase 2postbariatric hypoglycemia

Trial sponsors

  • Vogenx

    Company2 trialsPhase 251 people

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 11 paper in 12 months
bioRxiv

Canagliflozin reduced calcium buildup in mouse arteries

In experiments in mice fed a high-phosphate diet, canagliflozin reduced artery calcification while two related drugs did not.In experiments in mice fed a high-phosphate diet, canagliflozin reduced artery calcification while two related drugs did not.

Preprint: mouse studyCanagliflozin